 I'm going to present this update of the trial, which I think is known to many of you. It's the phase three trial in advance and metastatic kidney cancer of the volumab against everolimus in patients that have received anti-angiogenic therapy beforehand. Bob Motser is the PI on this study. These are my disclosures. As you all know, the volumab is a fully humanized IgG anti-PD1 antibody that specifically prevents the interaction of the ligands PDL1 and PDL2 with the receptor PD1. Are you also, I'm sure, aware that in the phase one trials the anti-PD1 showed considerable activity in renal cell cancer as well as other tumor types such as melanoma and non-small cell lung cancer. Everolimus is also well known to the audience. It's approved both in Europe and in the US for relapsed treatment after anti-angiogenic therapy with a doubling of the PFS when compared against placebo in a randomized trial. This study, which I guess is known colloquially as Check 25, has an interesting entry criteria in that everybody must have tissue available and it must be fairly fresh tissue or recent tissue before randomization so that the PDL1 expression can be assessed prior to randomization. This is the schema of the trial. Patients have to progress on previous anti-angiogenic therapy or within six months. The randomization is one-to-one as you see. RMA is Nivolumab. Given every two weeks, Everolimus is given a standard dose of 10 milligrams a day. Treatment is until progression or toxicity. The primary endpoint of this study is overall survival. The hazard ratio that we're aiming at is 0.76 which gives us a 32% increase in median overall survival between Nivolumab and Everolimus. The primary objective is, as I said, the duration of OS and as well as secondary endpoints of PFS and overall response rate, the duration of the overall response rate is going to be compared in the two groups, the PDL1 expressing and the PDL1 not expressing group, which is why the patients are stratified for PDL1 expression before randomization. Key inclusion criteria are really very standard. The only thing I think that's worth pointing out is that patients can have one or two prior anti-angiogenic therapies but cannot have more than three prior systemic therapies in all. Exclusion criteria, no history of CNS metastases. Prior treatment with PDL1, anti-PDL1, anti-CD137 and anti-CDR4 antibodies are not allowed. Thank you. These are the acknowledgments.